<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250723066612N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-11-06</date_registration>
      <primary_sponsor>Deputy of Research, Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of Crestal Bone Loss in 2 groups with different Seating Torque in the same implant system</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of Crestal Bone Loss in 2 groups with different Seating Torque in the same implant system</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-11-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>48</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/85145</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Stratified randomization (Stratified randomization) is performed using the website http://www.graphpad.com/quickcalcs/index.cfm.
Central randomization (Central randomization) is performed, Blinding description: Double-blinding is implemented such that both the participants and the researchers—including those involved in selection, data collection, and outcome assessment—are blinded to the group allocation of each individual. In other words, neither the patient nor the research team is aware of the implant’s seating torque value assigned to the participant, ensuring the prevention of any bias or influence on the study outcomes.</study_design>
      <phase>N/A</phase>
      <hc_freetext>The amount of crestal bone loss around the implant.</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group: In the intervention group, implants will be placed with an insertion torque ranging from 55 to 60 Ncm. All patients in this group will receive Neodent implants, which will be positioned using a subcrestal, two-stage surgical protocol. Immediately following the surgery, a baseline radiograph will be obtained utilizing the paralleling technique. The second radiograph will be captured four months post-surgery, coinciding with the second-stage procedure for the connection of the healing abutment, and will be taken using the identical paralleling technique. Intervention 2: Intervention Group: In the intervention group, implants will be placed with an insertion torque ranging from 25 to 30 Ncm. All patients in this group will receive Neodent implants, which will be positioned using a subcrestal, two-stage surgical protocol. Immediately following the surgery, a baseline radiograph will be obtained utilizing the paralleling technique. The second radiograph will be captured four months post-surgery, coinciding with the second-stage procedure for the connection of the healing abutment, and will be taken using the identical paralleling technique.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
IPD:
Raw data after cleaning included study variables such as demographic information, type of intervention, and outcomes for each individual patient
Study protocol:
Complete text of study protocol including objectives, study design, randomization and blinding methods, inclusion/exclusion criteria, definitions, and measurement tools.
Statistical Analysis Plan:
Detailed description of statistical methods, software used, models, and assumptions for tests.
Informed Consent Form:
Fully signed informed consent forms by participants or template consent form.
Clinical Study Report:
Comprehensive report including results, discussion, conclusions, patient data summary, and statistical analyses.

When:
Participant Data File (IPD):
From 6 months after the publication of the main study results for at least 5 years.
Study Protocol:
Available simultaneously with main study publications and archived permanently.
Statistical Analysis Plan:
Available after publication of primary results, for at least 5 years.
Informed Consent Form:
Maintained permanently after data collection is completed and publication is permitted.
Clinical Study Report:
Available after article publication and retained for at least 5 years.

To whom:
Participant Data File (IPD):
Official research center members, researchers with approved related research proposals, and other researchers upon ethical committee and research team approval. 
Study Protocol:
Open access for all researchers and scientific audiences without restrictions.
Statistical Analysis Plan:
Researchers involved in further analyses or meta-analyses with approved requests.
Informed Consent Form:
Only study team members and ethical committees.
Clinical Study Report:
Relevant researchers, regulatory bodies, scientific users for legitimate purposes.

Conditions:
Participant Data File (IPD):
Strictly for research purposes such as secondary analyses or meta-analyses with protection of participant confidentiality and anonymity.
Study Protocol:
For study review, educational use, and as a reference for similar studies.
Statistical Analysis Plan:
For reviewing analytical approaches and use in similar research.
Informed Consent Form:
Verification of ethical compliance in the study.
Clinical Study Report:
Reviewing results, use in systematic reviews, research projects.

Where to obtain:
Participant Data File (IPD):
Written request to the responsible for the research or the Vice President for Research at Mashhad University of Medical Sciences at the email address RAMResearch@mums.ac.ir
Study Protocol:
Download via official research center website or by email request.
Statistical Analysis Plan:
Written request to data analysis lead at the research center.
Informed Consent Form:
Internal request with ethical committee review if needed.
Clinical Study Report:
Written request reviewed and approved by research group.

How to obtain:
Participant Data File (IPD):
Initial evaluation by research team, ethics committee approval, signing a data use agreement, and delivery after confidentiality agreements are in place.
Study Protocol:
Automatic/manual sending upon email request without special authorization.
Statistical Analysis Plan:
Review of the request based on purpose, approval, and confidentiality agreement before delivery
Informed Consent Form:
Formal permission required; not available to external parties to ensure confidentiality.
Clinical Study Report:
Request assessment and permission under confidentiality agreements.

Comments:
Participant Data File (IPD):
Commercial use is prohibited unless explicitly approved in agreements.
Study Protocol:
Provided in PDF format
Statistical Analysis Plan:
May include explanatory sessions if needed.
Informed Consent Form:
Personal identifiers are removed or coded for privacy.
Clinical Study Report:
Delivered electronically in PDF or suitable formats.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nafiseh Nikzat</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.33,jahed 1</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9184313827</zip>
        <telephone>+98 912 963 0764</telephone>
        <email>nikzatnafiseh@gmail.com</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nafiseh Nikzat</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.33,jahed 1</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9184313827</zip>
        <telephone>+98 912 963 0764</telephone>
        <email>nikzatnafiseh@gmail.com</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients referred to the Implant Department of the Faculty of Dentistry, Mashhad
Patients who have sufficient bone volume for implant placement
Consent to participate in the study</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Consumption of narcotic drugs and addiction
Use of drugs affecting bone osteointegration
Having systemic diseases
Having periodontal disease</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group: In the intervention group, implants will be placed with an insertion torque ranging from 55 to 60 Ncm. All patients in this group will receive Neodent implants, which will be positioned using a subcrestal, two-stage surgical protocol. Immediately following the surgery, a baseline radiograph will be obtained utilizing the paralleling technique. The second radiograph will be captured four months post-surgery, coinciding with the second-stage procedure for the connection of the healing abutment, and will be taken using the identical paralleling technique.</i_keyword>
      <i_keyword>Intervention Group: In the intervention group, implants will be placed with an insertion torque ranging from 25 to 30 Ncm. All patients in this group will receive Neodent implants, which will be positioned using a subcrestal, two-stage surgical protocol. Immediately following the surgery, a baseline radiograph will be obtained utilizing the paralleling technique. The second radiograph will be captured four months post-surgery, coinciding with the second-stage procedure for the connection of the healing abutment, and will be taken using the identical paralleling technique.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The amount of crestal bone loss. Timepoint: The level of the crestal bone will be measured immediately following implant placement and subsequently at 4 months post-operation. Method of measurement: At the specified time points, a parallel periapical radiograph will be obtained, and subsequently, the crestal bone level will be compared.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Deputy of Research, Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-10-12</approval_date>
        <contact_name>Research Ethics Committee, School of Dentistry, Mashhad University of Medical Sciences</contact_name>
        <contact_address>Mashhad School of Dentistry, Opposite Mellat Park, Vakil Abad Blvd. Beginning, Mashhad Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
